FDA accepted a New Drug Software for dordaviprone for recurrent H3 K27M-mutant diffuse glioma beneath Precedence Evaluate.
The Meals and Drug Administration (FDA) has reportedly accepted a New Drug Software looking for accelerated approval for dordaviprone (ONC201) for the therapy of sufferers with recurrent H3 K27M-mutant diffuse glioma.
The appliance has been granted Precedence Evaluate and has been assigned a Prescription Drug Person Price Act goal motion date of Aug. 18, in accordance with a information launch issued by dordaviprone’s producer, biopharmaceutical firm Chimerix.
“This vital milestone brings us one step nearer to our objective of accelerating entry to the primary drugs particular to sufferers identified with recurrent H3 K27M-mutant diffuse glioma,” mentioned Mike Andriole, Chief Government Officer of Chimerix, in an announcement within the information launch. “Sufferers with this type of high-grade glioma face a really troublesome prognosis with few therapy choices past palliative care. Our workforce is working expeditiously with FDA to facilitate their evaluate as we concurrently put together for a possible business launch with a purpose to guarantee fast availability to sufferers in want.”
Glossary:
New Drug Software: in accordance with the FDA, that is the automobile by which drug sponsors formally suggest that the FDA approve a brand new pharmaceutical on the market and advertising and marketing in the USA.
Precedence Evaluate: a designation that, in accordance with the FDA, will direct total consideration and sources to the analysis of purposes for medication that, if authorized, can be vital enhancements within the security or effectiveness of the therapy, analysis or prevention of significant circumstances when in comparison with commonplace purposes.
Prescription Drug Person Price Act goal motion date: the deadline for the FDA to approve a brand new drug.
Quick Observe Designation: a course of designed to facilitate the event, and expedite the evaluate of medication to deal with critical circumstances and fill an unmet medical want, in accordance with the FDA.
Orphan Drug Designation: a designation, in accordance with the FDA, for a drug or organic product to forestall, diagnose or deal with a uncommon illness or situation, qualifying sponsors for incentives reminiscent of tax credit for scientific trials, exemption from consumer charges and potential seven years of market exclusivity.
When Chimerix introduced the submission of its New Drug Software for accelerated approval to the FDA for dordaviprone for sufferers with recurrent H3 K27M-mutant diffuse glioma in December 2024, Andriole acknowledged in a information launch that the drug may have a possible business launch in the USA in 2025.
Dordaviprone, Chimerix famous, has already obtained Uncommon Pediatric Illness Designation for H3 K27M-mutant glioma and has utilized for a Uncommon Pediatric Illness Precedence Evaluate Voucher within the New Drug Software submission.
Moreover, dordaviprone has been granted each Quick-Observe Designation and Orphan Drug Designation in the USA.
In a 2024 article on the part 3 ACTION research of dordaviprone in sufferers with newly identified H3 K27M-mutant diffuse glioma printed in Neuro-Oncology, researchers famous that H3 K27M-mutant diffuse glioma primarily impacts youngsters and younger adults. The illness is related to a poor prognosis, with no efficient systemic remedy presently out there.
Dordaviprone, researchers famous, has demonstrated efficacy in sufferers with recurrent illness.
The drug is described within the press launch as a novel, first-in-class small molecule imipridone that selectively targets mitochondrial protease ClpP and dopamine receptor D2.
In keeping with the Nationwide Most cancers Institute, dordaviprone is presently being evaluated in seven scientific trials as a monotherapy and together with different medication for the therapy of ailments together with colorectal most cancers, meningioma, endometrial most cancers, myelodysplastic syndrome, peritoneal most cancers and gliomas.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
